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Abstract: Cobalamin deficiency is common in patients with Crohn’s disease (CD).
Intramuscular cobalamin continues to be the standard therapy for the deficiency and maintenance
treatment in these patients, although oral route has been demonstrated to be effective in other
pathologies with impaired absorption. Our aims were to evaluate the efficacy of oral therapy in the
treatment of cobalamin deficiency and in long-term maintenance in patients with Crohn’s disease.
We performed a multicenter retrospective cohort study that included 94 patients with Crohn’s disease
and cobalamin deficiency. Seventy-six patients had B12 deficiency and 94.7% of them normalized
their cobalamin levels with oral treatment. The most used dose was 1 mg/day, but there were
no significant differences in treatment effectiveness depending on the dose used (≥1 mg/24 h vs.
<1 mg/24 h). Eighty-two patients had previous documented B12 deficiency and were treated with
oral B12 to maintain their correct cobalamin levels. After a mean follow-up of 3 years, the oral route
was effective as maintenance treatment in 81.7% of patients. A lack of treatment adherence was
admitted by 46.6% of patients in who the oral route failed. In conclusion, our study shows that oral
cyanocobalamin provides effective acute and maintenance treatment for vitamin B12 deficiency
caused by CD with or without ileum resection.
Keywords: vitamin B12 deficiency; cobalamin deficiency; Crohn’s disease; ileal resection;
oral treatment; acute treatment; maintenance treatment
1. Introduction
Vitamin B12 (cobalamin) is a water-soluble vitamin that is essential for DNA synthesis, effective
erythropoiesis, nervous system maintenance, and metabolism of protein, fat, and carbohydrate [1].
Humans cannot synthesize it, and hence need to obtain it through the diet, with it found almost
exclusively in food of animal origin [2]. The manifestation of cobalamin deficiency ranges from subtle,
non-specific clinical features to serious neurological and neuropsychiatric complications; because of
that it is important to ensure an adequate intake and to provide a suitable screening for B12 deficiency
in patients at risk [1]. A typical Western diet contributes 3–30 µg of B12 per day, of which 1–5 µg are
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absorbed, towards the recommended dietary allowance of 1 to 3 µg/day. Also, the body storage is
relatively high (2000–5000 µg), which explains why clinical manifestations of B12 deficiency often
appear late. Metabolism of this vitamin is complex and is made up of many processes, defects in any
one of which can lead to deficiency [3].
Crohn’s disease (CD) is a chronic inflammatory gastrointestinal disorder that can affect any
segment of the gastrointestinal tract, including the terminal ileum, where most of the absorption (98%)
of B12 occurs. The reported prevalence of B12 deficiency in CD ranges from 5.6% to 38% and main
causes of this deficiency are ileal resection and ileal disease (activity or fibrosis) [4–11].
The classical treatment for B12 deficiency is parenteral administration, in most countries
intramuscular injection. However, a study performed in 1968 showed that 0.5% to 4% of radioactively
labeled oral B12 can be absorbed along the entire intestine by passive diffusion in healthy people
and in patients with pernicious anemia [12]. Although in normal conditions this may be a secondary
mechanism, it may gain importance when the active mechanism mediated by intrinsic factor is affected.
Several later randomized trials compared high oral doses (1000 to 2000 µg/day) with parenteral
administration in patients with pernicious anemia, atrophic gastritis, or ileum or gastric surgery have
shown that high daily doses of oral B12 have similar or better short-term improvements in B12 levels
and symptoms resolution than parenteral administration [13–15]. In patients with CD, oral therapy
may be as effective as parenteral, but is currently underexplored. Therefore, the aims of our study are:
(1) to evaluate the efficacy of oral therapy in the treatment of vitamin B12 deficiency in patients with
Crohn’s disease and (2) to analyze its efficacy in long-term maintenance treatment.
2. Materials and Methods
2.1. Definition of Terminology
The diagnosis of CD was performed in the patients included in our study according to the
Lennard-Jones definition [16], which includes four groups of diagnosis criteria: clinical, radiological,
endoscopic, and pathological criteria. The presence of at least two criteria is required and the pathology
is the definitive one. Moreover, the sub-classification of Crohn’s disease by phenotype was performed
according to Montreal classification [17] that considered age of onset (A; A1: below 16 years old,
A2: between 17–40 years old, and A3: >40 years old), disease location (L; L1: ileal, L2: colonic, L3: ileocolonic,
and L4: isolated upper disease modifier), and disease behavior (B; B1: non-stricturing and non-penetrating,
B2 stricturing, B3 penetrating, and p: perianal disease modifier) as the predominant phenotypic elements.
The diagnosis of B12 deficiency was defined according to local laboratory criteria as serum
cobalamin ≤200 pg/mL. Serum cobalamin concentrations were measured using chemiluminescence,
with the assay from Beckman Coulter, which has a coefficient of variation <12% and a very good
correlation with radioimmunoassay (r > 0.95).
Finally, the diagnosis of anemia and macrocytosis were performed according to international
standards and local laboratory criteria. In adults, anemia is defined as a hemoglobin (Hb) levels
below 12 gr/dL for non-pregnant women, 11 gr/dL for pregnant women, and 13 gr/dL for men [18]
and macrocytosis is defined as the presence of macrocytes on a blood film, together with a raised mean
corpuscular volume (MCV) (>98 fL) [18].
2.2. Study Population
This investigation is a cohort study with retrospective data collection conducted in four general
hospitals integrated into the Spanish National Health System.
To address our aims, we distinguished two cohorts of patients: (1) patients with B12 deficiency
and (2) patients with previous B12 deficiency who required maintenance treatment. Thus, to address
our first aim, we included in our study patients attending our adult Inflammatory Bowel Disease
Units diagnosed with CD and B12 deficiency who had been treated with B12 by oral route between
January 2001 and November 2012. To address our second aim, we included patients attending our
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adult Inflammatory Bowel Disease Units diagnosed with CD and in who B12 deficiency was treated
successfully with oral or intramuscular B12 between January 2001 and November 2012, but where
maintenance treatment had then been conducted orally.
We included 94 patients with CD and B12 deficiency in our study, with a slight predominance
of men. All patients were white and the average age of participants was 45 ± 13 years.
Twenty-seven (28.7%) patients were active smokers. In relation to characteristics of CD at diagnosis
of our patients, and according to Montreal Classification, more than 95% of them had disease in the
terminal ileum (L1 or L3). Two (2/94) patients also had upper gastrointestinal disease and 11 (11/94)
also had perineal disease. Finally, a surgical resection of the ileum had been performed in 24 patients
(25.5%). Data about resection length were not available in all patients. Table 1 shows clinical and
demographic characteristics of the study population.
Notably, none of the patients had neurological symptoms secondary to B12 deficiency. Also, none
of the included patients had a previous diagnosis of pernicious anemia, and only one patient had prior
history of gastric surgery.
Table 1. Clinical and demographic characteristics of the study population.
Patients Demographics Overall Study Population(94 Patients) n (%)
Cohort B12 Deficiency
Treatment (76 Patients) n (%)
Cohort Maintenance
Treatment (82 Patients) n (%)
Sex (male) 52 (55.3) 42 (55.3) 45 (54.9)
Age (years)
Mean ± standard deviation 45 ± 13 45 ± 13 44 ± 13
Median, interquartile range 43, 35–53 42, 35–54 44, 35–53
Tobacco
Active smokers 27 (28.7) 21 (27.6) 25 (30.5)
Non-active smokers 67 (71.3) 55 (72.4) 57 (69.5)
Montreal Classification
A1 4 (4.3) 2 (2.6) 4 (4.9)
A2 65 (69.1) 52 (68.4) 56 (68.3)
A3 25 (26.6) 22 (28.9) 22 (26.8)
L1 45 (47.9) 37 (48.7) 40 (48.8)
L2 4 (4.2) 4 (5.3) 3 (3.7)
L3 45 (47.9) 35 (46.0) 39 (47.5)
B1 36 (38.3) 29 (38.1) 31 (37.8)
B2 41 (43.6) 35 (46.1) 35 (42.7)
B3 17 (18.1) 12 (15.8) 16 (19.5)
Perineal disease 11 (11.7) 2 (2.6) 11 (13.4)
Upper gastrointestinal disease 2 (1.88) 1 (1.31) 2 (2.43)
Ileal resection 24 (25.5) 21 (27.6) 21 (25.6)
2.3. Therapeutic Regimens
The different vitamin B12 oral treatment regimens used for treatment of B12 deficiency and for
maintenance treatment are shown in Tables 2 and 3.
Table 2. Vitamin B12 oral treatment regimens used for treatment of B12 deficiency.
Brand Name Qualitative and Quantitative Composition Dosage Patients n
BENEXOL© B12 1 mg, B6 250 mg, B1 250 mg
1 tablet/24 h 38
1 tablet/12 h 6
1 tablet/8 h 3
FOLIDOCE© B12 0.002 mg, folic acid 0.4 mg 1 tablet/12 h 2
HIDROXIL© B12 0.5 mg, B6 250 mg, B1 250 mg 1 tablet/24 h 1
NEURODAVUR© B12 2.5 mg, B6 250 mg, B1 250 mg 1 tablet/24 h 3
NEUROMADE© B12 1 mg, B6 50 mg, B1 50 mg 1 tablet/24 h 6
OPTOVITE© B12 1 mg
1 ampule/24 h 9
2 ampule/7 days 8
Benexol© (Bayer Hispania, Barcelona, Spain). Folidoce© (Italfarmaco España, Madrid, Spain). Hidroxil©
(Almirall España, Barcelona, Spain). Neurdavur© (Davur laboratorios, Madrid, Spain). Neuromade
(Teofarma, Barcelona, Spain). Optovite© (Normon, Madrid, Spain).
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Table 3. Vitamin B12 oral treatment regimens used for maintenance treatment.
Brand Name Qualitative and Quantitative Composition Dosage Patients n
BENEXOL© B12 1 mg, B6 250 mg, B1 250 mg
1 tablet/24 h 22
1 tablet/48 h 1
2 tablet/7 days 17
FOLIDOCE© B12 0.002 mg, folic acid 0.4 mg 1 tablet/12 h 2
NEURODAVUR© B12 2.5 mg, B6 250 mg, B1 250 mg 1 tablet/24 h 8
NEUROMADE© B12 1 mg, B6 50 mg, B1 50 mg 1 tablet/24 h 9
OPTOVITE© B12 1 mg 2 ampule/7 days 23
Benexol© (Bayer Hispania, Barcelona, Spain). Folidoce© (Italfarmaco España, Madrid, Spain). Neurdavur© (Davur
laboratorios, Madrid, Spain). Neuromade (Teofarma, Barcelona, Spain). Optovite© (Normon, Madrid, Spain).
2.4. Statistical Analysis
An initial exploratory analysis of all clinical variables was carried out. Continuous variables were
expressed as the mean and standard deviation or median and interquartile range; whereas, qualitative
variables were expressed as frequencies and percentages. The relationship between qualitative
variables was evaluated with the chi-square test or the Fisher exact test if the expected effective
cases were less than 5. The student t-test or Mann-Whitney U test was employed for comparing
means of two independent groups. Normality was tested using the Kolmogorov-Smirnov test. For all
tests, a two-sided p-value < 0.05 was considered statistically significant. The statistical analyses were
performed using SPSS software v22.0 for Windows.
3. Results
3.1. Effectiveness of Oral Treatment in Vitamin B12 Deficiency
Seventy-six patients of the overall population included (94 patients) had vitamin B12 deficiency
and were treated with oral B12 therapy to correct their deficiency. In these patients, the mean serum
cobalamin concentration before oral treatment was 152.83 ± 34.09 pg/mL (median 157, interquartile
range of 132–174.5 pg/mL). Seventy-two (94.7%) patients normalized their vitamin B12 levels
(>200 pg/mL) after mean treatment duration of 193± 278 days (median 120, interquartile range 78–191).
The mean serum cobalamin concentration after treatment increased to 398.14 ± 208.90 pg/mL
(median 354.59, interquartile range: 242 to 474.50). Figure 1 shows the evident change of B12 levels
and Table 4 cobalamin levels of each patient before and after treatment. In relation to hematologic
manifestations of B12 deficiency, before oral B12 treatment, 19.7% (15) of patients had anemia
(mean concentration of Hb: 13.61 ± 1.67), but no patient had macrocytic anemia. The erythrocyte MCV
was elevated in 14 (18.4%) patients, although without anemia, with a mean of MCV of 91.54 ± 7.58.
After treatment with oral vitamin B12, there were no significant changes in Hb concentration nor in MCV.
Folic acid levels (ng/mL), before and after treatment with oral cyanocobalamin, are shown in
Supplementary Table 1 (Table S1).
In the subgroup of patients with ileal resection (21 patients), the mean serum cobalamin
concentration before oral treatment was slightly lower than in patients without ileum surgery, but the
differences were non-significant (151.43 ± 39.37 pg/mL vs. 153.36 ± 3.23 pg /mL, p > 0.05). Two of
the four patients that did not normalize B12 levels after oral treatment had ileum resection. After oral
B12 treatment, the mean serum cobalamin concentration increased significantly in patients with ileal
resection and in patients without prior surgery (368.38 ± 189.45 pg/mL and 409.51 ± 216.42 pg/mL).
There were no significant differences in the B12 levels reached between both groups.
Different oral treatment regimens were used; the daily dose of B12 used ranged from 0.004
to 3 mg, with 1 mg daily being the most used dose (in 53 patients, 69.7%). Fifty-nine patients
(77.6%) were treated with doses of oral B12 ≥1 mg/day. There were no significant differences in oral
treatment effectiveness in the normalization of B12 levels depending on the dose used (≥1 mg/24 h vs.
<1 mg/24 h; 94.9% vs. 94.1%, p > 0.05). The different regimens used are shown in Table 2.
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Table 4. Serum cobalamin levels (pg/mL) before and after acute treatment with oral cyanocobalamin.
Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38
Before 46 72 79 86 90 104 104 105 111 116 117 118 119 119 119 121 128 128 129 135 136 137 137 139 139 139 141 142 151 152 153 153 155 156 156 156 157 157
After 177 229 554 333 464 488 273 232 202 230 202 1369 622 375 233 446 222 247 452 402 367 313 436 305 251 394 219 203 198 779 187 294 627 204 228 360 803 562
Patient 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76
Before 157 159 159 161 163 164 165 166 168 169 170 170 170 171 173 173 173 174 174 175 175 176 177 181 184 186 192 193 196 199 200 200 200 200 200 200 200 200
After 216 321 223 350 360 391 934 296 471 294 349 841 402 478 497 182 286 623 478 761 246 507 252 238 218 296 359 380 337 411 380 259 660 744 430 373 287 647
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Figure 1. Serum cobalamin lev l ( mL) before and afte treatment with oral cyanocobalamin.
* Extreme value (1369 pg ).
3.2. Effectiveness of Oral Route in Maintenance Treatment
Eighty-two patients with CD and previous documented B12 deficiency were treated with oral
B12 to maintain their correct cobalamin levels. Seventy-eight percent of them (64/82) had been
previously treated with oral B12 to correct the deficiency and 22% (18/82) with intramuscular
B12 treatment. The mean serum cobalamin concentration before oral maintenance treatment
was 429.39 ± 222.65 pg/mL (median 368, interquartile range of 273–489 pg/mL). After a mean
follow-up of 1091 ± 841 days (median 892, interquartile range 375–1765), the oral B12 route was
effective to keep serum cobalamin levels >200 pg/mL in 81.7% (67) of patients. The mean s rum
cobalamin co centration after follow-up was 364.45± 226.62 pg/mL (median 298.5, int rquartile range
of 214–4 0 pg/mL). See Figure 2 and Table 5. Interestingly, a lack of oral B12 tre t ent adher nce was
ad itted by almos half (46.6%, 7/15) of the patients who failed to keep normal levels of cobalamin
with the oral maintenance treatment.
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Figure 2. Serum cobalamin levels (pg/mL) during maintenance therapy; at the beginning of follow-up
and at the end of follow-up. * Extreme values (1513 pg/mL, 1500 pg/mL and 1304 pg/mL, see Table 5).
The daily dose of B12 used as mai t nance tr atment ra ed from 0.004 to 2.5 mg, wit 2 mg
weekly (0.28 mg/d y) being the most us d dos (i 40 patients, 48.7%). Th re were no significant
differences in oral maintenance treatment effectiveness dep nding on the dose used (>0.28 mg/24 h
vs. ≤0.28 mg/ 24 h; 83.4% vs. 80%, p > 0.05). The different oral treatment regimens used are shown
in Table 5.
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Table 5. Serum cobalamin levels (pg/mL) during maintenance therapy; at the beginning of follow-up and at the end of follow-up.
Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41
Beginning 202 202 202 204 214 216 218 222 223 228 229 230 232 238 244 246 247 251 252 259 273 286 287 294 294 296 296 304 305 305 313 321 337 338 349 350 359 360 360 364 367
End 168 255 155 271 214 422 211 295 310 193 201 224 289 491 288 209 413 263 176 174 303 279 287 294 194 463 372 359 233 166 186 176 283 316 454 293 359 468 270 364 215
Patient 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82
Beginning 369 371 373 375 380 380 389 391 394 402 411 430 432 436 446 452 464 471 478 488 489 497 532 554 560 587 622 623 645 647 660 695 744 761 803 841 885 934 1065 1500
End 897 173 177 214 302 239 290 154 354 409 600 524 387 496 1304 177 239 229 365 709 398 460 167 535 496 413 416 391 494 729 440 522 328 351 1513 167 214 616 217 767
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4. Discussion
The traditional treatment of vitamin B12 deficiency is intramuscular injection, however, this
vitamin may be offered orally. The increasing evidence that supports the use of oral vitamin B12 as
an effective alternative to parenteral administration prompted the spread of oral administration in
some countries, such as Sweden or Canada. However, in the rest of the world, intramuscular route
remains the most used. Indeed, controversy still surrounds the advantages and effectiveness of the
oral therapy [19]. Three randomized controlled trials (RCTs) have compared oral and intramuscular
vitamin B12 in patients with B12 deficiency from different causes and, although relatively short in
duration (<4 months) and of small sample size (158 patients in total), showed that oral was as effective
as intramuscular therapy in normalizing B12 levels and hematological alterations [13–15]. We want to
emphasize that two of these RCTs excluded patients with inflammatory bowel disease [13,14] and the
other included patients with CD, but the number was not shown in the publication [15]. Our large
case series specifically evaluates oral administration route in CD and shows that oral cyanocobalamin
provides effective acute and maintenance treatment for vitamin B12 deficiency caused by CD with
or without ileum resection. Moreover, our follow-up periods are long, unlike previous studies.
We found no significant changes in Hb concentration nor MCV after oral B12 therapy. It is important
to note that, in our study, 20% of patients had anemia but none had macrocytic anemia, probably
because most anemia was not attributable to B12 deficiency. In CD, cobalamin deficiency is rarely
associated with anemia and most anemia is attributable to iron deficiency or chronic inflammation [5].
To our knowledge, there is a unique report that evaluated the efficacy of oral B12 replacement in
CD. This study, which was published in 2014 in the “letters to the editor” section by Plener et al.,
concluded that 27 patients with low baseline values achieved normal serum B12 levels with oral B12
therapy and nine maintained them [20]. The data provided by authors are scarce. We want to note
that, in 2013, we had presented the preliminary data for our study in the annual congress of Spanish
Gastroenterology Association and also in Congress of European Crohn’s and Colitis Organization.
Therefore, we believe that our study was the first in evaluating oral B12 therapy in Crohn’s disease
patients [21,22].
In our opinion, it is necessary to know if oral treatment is effective in patients with CD.
These patients may have significant portions of ileum affected by inflammation or resected and thus the
active B12 absorption may have dramatically decreased and even passive absorption may be affected.
Until now, most of the patients included in previous studies have had pernicious anemia, atrophic
gastritis, gastric surgery, or low diet intake, ignoring patients with CD [13–15,23,24]. The possibility
of taking an oral preparation would also allow patient preferences to be taken into account when
deciding on what treatment to prescribe. Oral administration should provide patients with greater
autonomy, improve treatment satisfaction, reduce treatment costs, and improve safety in anticoagulated
patients [23,25–27]. Nyholm et al. showed that all patients included in their study found oral therapy
to be acceptable or highly acceptable and that 87% preferred oral to intramuscular therapy [23].
A Canadian study of primary care found that 73% of patients taking intramuscular B12 were willing
to do a trial switch to oral route and after 6 months, 71% wished to remain on oral treatment
permanently [25]. In relation to cost, there is little difference in the cost of oral versus intramuscular
therapy when the medication alone is considered. However, intramuscular administration often
involves a special trip to a health facility or a home visit by a health professional to administer the
injection. Oral treatment could therefore save considerable Health Service resources. For example,
a Canadian study [27] estimated that converting patients aged over 65 years on B12 replacement from
the intramuscular to oral form could save between $2.9 and $17.6 million (2.5 and 15.3 million Euro)
over five years in Ontario alone. In our public National Health System, B12 ampules are covered under
all provincial health drug plans, while B12 tablets are not covered. Thus, oral B12 tablets probably
save public Health Service resources, but are more expensive for Spanish patients. Because of that,
one of the most used formulations in our study for maintenance treatment is B12 ampules, but by
oral route. In our opinion, all advantages and disadvantages of both administration routes must
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be evaluated and explained to the patient. Although oral administration seems to be easy, effective,
and less costly than the intramuscular route, some patients may benefit from traditional administration.
For example, intramuscular therapy may be a better option to ensure timely administration in patients
with non-adherence to oral medication. In our study, we detected that 8.5% of our patients in
maintenance treatment had low-adherence, which resulted in treatment failure. This low adherence
could be explained by some characteristics of our population related to low treatment adherence in
patients with CD: a population that includes many young adults, many that take multiples drugs
and with asymptomatic B12 deficiency [28]. Briefly, evaluating risk factors for low adherence to the
different routes of administration is important before choosing one of them.
The oral dosage to be used in patients with CD is not yet to established. In the three RCTs that
evaluate the oral therapy [11–13] and in most case series [20,23,24], high oral doses (1000–2000 µg/day)
were used, but in these studies very few patients with CD were included. Eussen et al. showed in their
dose-finding trial that the lowest dose of oral vitamin B12 required to normalize mild deficiency in older
people was more than 200 times greater than the recommended dietary intake (3 µg/day) [29]. In view
of the estimated 1% of total absorption by passive diffusion, a 1000 µg daily dose is recommended in
patients with pernicious anemia. However, patients with CD and/or short ileal resection probably
maintain, although not intact, a percentage of their active B12 absorption, and thus lower doses
may be sufficient, especially in maintenance treatment. In our study, 2 mg weekly (0.28 mg daily)
for maintenance treatment was the most used dosage (48.7%) with high effectiveness. In fact, there
were no significant differences between this dosage and other higher dosages. For treatment of the
deficiency, we used high doses, with 1 mg being the most used dose (69.7%) but there were also no
significant differences between this dosage and other lower dosages. Also, our patients had good
tolerability without adverse events after high oral dose of vitamin B12.
Finally, the study’s strengths include its large sample size and long follow-up period that allow for
the evaluation of long-term efficacy. We also acknowledge several limitations. It is a retrospective study
that did not includeB12 deficient patients with neurological symptoms. Also, functional biomarkers of
the deficiency (methylmalonic acid and homocysteine concentrations) were not taken into account as
diagnostic markers and outcome variables because these are not normally determined in our country,
either at diagnosis or during follow-up.
5. Conclusions
To our knowledge, the present study represents the first study that specifically evaluated the
role of oral administration route in the treatment of B12 deficiency in patients with CD, and also is
one of the largest cohorts of patients with B12 deficiency treated orally. According to our results,
oral administration of cyanocobalamin must be strongly considered and may be even the regimen of
choice to treat B12 deficiency in CD. It is effective as a means in which to treat deficiency and also
as a maintenance treatment, being well tolerated in these patients. Other studies are still required
to test if oral B12 is suitable in patients with neurological symptoms. The oral dosage to be used
in these patients is not yet fully established, but probably moderately high doses (1 mg/day) are
required for initial treatment and lower doses for maintenance treatment. A close monitoring with
clinical review and repeat vitamin B12 levels may help to establish the most adequate maintenance
doses. Patient preference is a factor of prime importance in the choice of administration route in
order to avoid low treatment adherence. Finally, further research is needed to avoid perpetuating oral
cyanocobalamin replacement as one of “medicine’s best kept secrets” [30].
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/9/3/308/s1,
Table S1: Serum cobalamin levels (pg/mL) and folic acid levels (ng/mL) before and after acute treatment with
oral cyanocobalamin.
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